[PDF][PDF] Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
PM LoRusso, AA Adjei, M Varterasian… - Journal of clinical …, 2005 - researchgate.net
PM LoRusso, AA Adjei, M Varterasian, S Gadgeel, J Reid, DY Mitchell, L Hanson, P DeLuca…
Journal of clinical oncology, 2005•researchgate.netPurpose This phase I study was undertaken to define the toxicity, pharmacokinetics,
pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-
molecule inhibitor of the dual-specificity kinases MEK (mitogen-activated protein kinase
kinase)-1 and MEK2, in patients with advanced malignancy.
pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-
molecule inhibitor of the dual-specificity kinases MEK (mitogen-activated protein kinase
kinase)-1 and MEK2, in patients with advanced malignancy.
Purpose
This phase I study was undertaken to define the toxicity, pharmacokinetics, pharmacodynamics, maximum tolerated dose (MTD), and clinical activity of CI-1040, a small-molecule inhibitor of the dual-specificity kinases MEK (mitogen-activated protein kinase kinase)-1 and MEK2, in patients with advanced malignancy.
researchgate.net